About: Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.29 (-3.78%)
ABOS NASDAQ Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals Inc share price
Atividade de preço de ABOS
Último preço
$ 2,290
Variação (24h)
-0,09 USD (3,78%)
Volume
806.62K
Volume (média 4 sem.)
-
Abertura
$ 2,40
Variação do dia
$ 2,29 - $ 2,52
Fechamento anterior
$ 2,38
Último negócio
29 Oct, 8:24 pm GMT+0
Atrasado
29 Oct, 8:24 pm GMT+0
ABOS price performance
Atrasado
29 Oct, 8:24 pm GMT+0
quote.marketSignals